{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:35:54Z","timestamp":1770492954699,"version":"3.49.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ccl.2022.06.008","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T04:12:55Z","timestamp":1663215175000},"page":"541-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Transthyretin Cardiac Amyloidosis"],"prefix":"10.1016","volume":"40","author":[{"given":"Dia A.","family":"Smiley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos M.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ccl.2022.06.008_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchf.2013.10.006","article-title":"Developing therapies for heart failure with preserved ejection fraction: current state and future directions","volume":"2","author":"Butler","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchf.2020.12.005","article-title":"The impact of patients with cardiac amyloidosis in HFpEF trials","volume":"9","author":"Oghina","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.ccl.2022.06.008_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"24","key":"10.1016\/j.ccl.2022.06.008_bib4","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2022.06.008_bib5","doi-asserted-by":"crossref","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, et\u00a0al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation inalpha2-macroglobulinandtau: a population-based autopsy study. Ann Med. 2008;40(3):232-239.","DOI":"10.1080\/07853890701842988"},{"issue":"24","key":"10.1016\/j.ccl.2022.06.008_bib6","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2022.06.008_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/13506129.2014.964858","article-title":"Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis","volume":"21","author":"Sipe","year":"2014","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.ccl.2022.06.008_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.ccl.2022.06.008_bib9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2141.2001.02999.x","article-title":"Amyloidosis: a convoluted story: historical review","volume":"114","author":"Kyle","year":"2001","journal-title":"Br J Haematol"},{"issue":"sup1","key":"10.1016\/j.ccl.2022.06.008_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/13506129.2017.1281116","article-title":"Transthyretin amyloidosis: a little history of hereditary amyloidosis","volume":"24","author":"Benson","year":"2017","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.ccl.2022.06.008_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2796.1992.tb00625.x","article-title":"History of amyloidosis","volume":"232","author":"Cohen","year":"1992","journal-title":"J\u00a0Intern Med"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1172\/JCI113966","article-title":"Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy","volume":"83","author":"Gorevic","year":"1989","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"issue":"Supplement_1","key":"10.1016\/j.ccl.2022.06.008_bib15","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1182\/blood-2019-129269","article-title":"Rationale and Design of a Phase 3 study to evaluate the efficacy and safety of ION-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)","volume":"134","author":"Falk","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","article-title":"Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis","volume":"15","author":"Bandera","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ccl.2022.06.008_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ccl.2022.06.008_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2796.2003.01173.x","article-title":"Hereditary transthyretin amyloidosis from a Scandinavian perspective","volume":"254","author":"Suhr","year":"2003","journal-title":"J\u00a0Intern Med"},{"issue":"7","key":"10.1016\/j.ccl.2022.06.008_bib21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2022.06.008_bib22","article-title":"Three new amyloidogenic TTR mutations: PRO12, GLU18, and VAL33. Neuromuscular Disord. Three new amyloidogenic TTR mutations: PRO12, GLU18, and VAL33 Neuromuscular Disord","volume":"6","author":"Booth","year":"1996"},{"key":"10.1016\/j.ccl.2022.06.008_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2017.09.001","article-title":"Ocular manifestations of familial transthyretin amyloidosis","volume":"183","author":"Reynolds","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib24","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccl.2022.06.008_bib26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"30","key":"10.1016\/j.ccl.2022.06.008_bib27","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC Cardiooncol"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib29","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis inpatients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ccl.2022.06.008_bib30","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"issue":"38","key":"10.1016\/j.ccl.2022.06.008_bib32","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ccl.2022.06.008_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.ccl.2022.06.008_bib34","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic stenosis and cardiac amyloidosis: JACC review topic of the week","volume":"74","author":"Ternacle","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"47","key":"10.1016\/j.ccl.2022.06.008_bib35","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","article-title":"Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?","volume":"37","author":"Galat","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcmg.2015.04.012","article-title":"Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis","volume":"9","author":"Longhi","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.ccl.2022.06.008_bib37","doi-asserted-by":"crossref","first-page":"e005066","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe Calcific aortic stenosis: prevalence and prognosis in patients undergoing Surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.ccl.2022.06.008_bib38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","article-title":"Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types","volume":"33","author":"Nativi-Nicolau","year":"2018","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12872-018-0952-8","article-title":"Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers","volume":"18","author":"Kyriakou","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"10.1016\/j.ccl.2022.06.008_bib40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00059-020-04904-4","article-title":"Amyloid cardiomyopathy","volume":"45","author":"Kristen","year":"2020","journal-title":"Herz"},{"issue":"2","key":"10.1016\/j.ccl.2022.06.008_bib42","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-019-1094-z","article-title":"Echocardiographic findings in cardiac amyloidosis: inside two-dimensional, Doppler, and strain imaging","volume":"21","author":"Di Nunzio","year":"2019","journal-title":"Curr Cardiol Rep"},{"issue":"14","key":"10.1016\/j.ccl.2022.06.008_bib43","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.mric.2019.04.005","article-title":"The role of cardiac MR imaging in the assessment of patients with cardiac amyloidosis","volume":"27","author":"Carvalho","year":"2019","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"2","key":"10.1016\/j.ccl.2022.06.008_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.ccl.2022.06.008_bib46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/13506129.2013.871250","article-title":"Bone scintigraphy with99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis","volume":"21","author":"Glaudemans","year":"2014","journal-title":"Amyloid"},{"issue":"24","key":"10.1016\/j.ccl.2022.06.008_bib48","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/dc.10370","article-title":"Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?","volume":"30","author":"Ansari-Lari","year":"2004","journal-title":"Diagn Cytopathol"},{"issue":"10","key":"10.1016\/j.ccl.2022.06.008_bib50","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine","year":"2014","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.ccl.2022.06.008_bib51","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.ccl.2022.06.008_bib52","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.ccl.2022.06.008_bib53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"issue":"13 Pt 1","key":"10.1016\/j.ccl.2022.06.008_bib54","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/0002-9149(85)90996-8","article-title":"Selective binding of nifedipine to amyloid fibrils","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol"},{"issue":"23","key":"10.1016\/j.ccl.2022.06.008_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000455","article-title":"Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American heart association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2022.06.008_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","article-title":"Digoxin use in cardiac amyloidosis","volume":"133","author":"Donnelly","year":"2020","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2022.06.008_bib57","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.hfc.2016.12.003","article-title":"Current concepts of cardiac amyloidosis: diagnosis, clinical management, and the need for collaboration","volume":"13","author":"Ritts","year":"2017","journal-title":"Heart Fail Clin"},{"issue":"11","key":"10.1016\/j.ccl.2022.06.008_bib58","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.ccl.2022.06.008_bib59","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience: atrial fibrillation in wild-type transthyretin amyloidosis","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10.1016\/j.ccl.2022.06.008_bib60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib61","first-page":"2490","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"119","author":"Dli","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccl.2022.06.008_bib62","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.ccl.2022.06.008_bib63","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.ccl.2022.06.008_bib64","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","author":"Towbin","year":"2019","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.ccl.2022.06.008_bib65","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.ccl.2022.06.008_bib66","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jacep.2020.05.027","article-title":"A\u00a0peak into the pace of cardiac amyloidosis","volume":"6","author":"Kochav","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"11","key":"10.1016\/j.ccl.2022.06.008_bib67","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ccl.2022.06.008_bib68","first-page":"351","article-title":"Hsu management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ccl.2022.06.008_bib69","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis: ICD in cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ccl.2022.06.008_bib70","doi-asserted-by":"crossref","unstructured":"Rehorn MR, Loungani RS, Black-Maier E, et al. Cardiac Implantable Electronic Devices: A Window Into the Evolution of Conduction Disease in Cardiac Amyloidosis. JACC Clin Electrophysiol 2020:6(9):1144-1154. doi:10.1016\/j.jacep.2020.04.020. Epub 2020 Aug 26. PMID: 32972550.","DOI":"10.1016\/j.jacep.2020.04.020"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib71","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2022.06.008_bib72","article-title":"The use of diflunisal for transthyretin cardiac amyloidosis: a review","author":"Ibrahim","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib73","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.ccl.2022.06.008_bib75","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccl.2022.06.008_bib76","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"issue":"24","key":"10.1016\/j.ccl.2022.06.008_bib77","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccl.2022.06.008_bib79","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2022.06.008_bib80","doi-asserted-by":"crossref","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865122000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865122000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:53:57Z","timestamp":1760007237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865122000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0733865122000327"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2022.06.008","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transthyretin Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2022.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}